AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Weave Communications, Inc.

$7.31 +$0.14 (+1.95%)
NYSE · 11 Sep 2026 20:00 UTC
Previous Close
$7.3
Day Range
$7.3$7.32
Year Range
$4.24$7.97
Market Cap
581.62M
AVG Volume
2.18M
Trailing/Forward PE
-28.85/29.54
PEG ratio
-0.63
Dividend Yield
-
Next Earnings Date
2026-11-04
Primary Exchange
New York Stock ExchangeUS
Revenue (USD) · TTM
0100M200M300M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q2257.79M
26 Q1248.72M
25 Q4239.02M
25 Q3229.79M
25 Q2220.83M
25 Q1212.95M
24 Q4204.31M
24 Q3195.84M
24 Q2187M
24 Q1178.08M
Net Income (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-20.54M
26 Q1-25M
25 Q4-28.05M
25 Q3-32.91M
25 Q2-30.13M
25 Q1-29.97M
24 Q4-28.35M
24 Q3-28.67M
24 Q2-29.94M
24 Q1-30.38M
Operating Income (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-21.26M
26 Q1-27.06M
25 Q4-30.61M
25 Q3-35.82M
25 Q2-33.51M
25 Q1-32.58M
24 Q4-31.41M
24 Q3-32.03M
24 Q2-33.42M
24 Q1-34M
EBITDA (USD) · TTM
-15M-10M-5M05M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q23.35M
26 Q1-7.5M
25 Q4-11.3M
25 Q3-13.26M
25 Q2-10.67M
25 Q1-9.46M
24 Q4-7.74M
24 Q3-8.07M
24 Q2-8.98M
24 Q1-9.3M
Cash Flows (USD) · TTM
-20M020M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q214.29M
26 Q19.59M
25 Q415.15M
25 Q316.15M
25 Q214.31M
25 Q130.63M
24 Q410.78M
24 Q37.58M
24 Q25.71M
24 Q1-14.57M
EPS (USD) · TTM
-0.6-0.4-0.2-024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-0.25
26 Q1-0.31
25 Q4-0.36
25 Q3-0.43
25 Q2-0.4
25 Q1-0.41
24 Q4-0.39
24 Q3-0.4
24 Q2-0.42
24 Q1-0.43
Expenses (USD) · TTM
0100M200M300MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q2210.5M
26 Q1209.5M
25 Q4205.31M
25 Q3202.92M
25 Q2194.26M
25 Q1188.42M
24 Q4180.67M
24 Q3174.08M
24 Q2168.39M
24 Q1160.1M
Shares Outstanding (USD) · TTM
-40M-30M-20M-10M010MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WEAV Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-28.06M
26 Q1-30.25M
25 Q4-32.1M
25 Q3-37.27M
25 Q2-35.37M
25 Q1-34.43M
24 Q4-32.22M
24 Q3-29.33M
24 Q2-27.5M
24 Q1-25.08M
Employee Count
02505007501K20212022202320242025
WEAV Employee Count by quarter
PeriodEmployee Count
2025904
2024854
2023844
2022806
2021889
Free Cash Flow Yield
0%2%4%6%8%med 2.48%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 262.46%
Sep 262.45%
Aug 262.46%
Aug 262.46%
Aug 263.29%
Aug 263.39%
Jul 261.87%
Jul 261.98%
Jul 261.69%
Jul 261.76%
Jul 261.85%
Jun 262.06%
Jun 262.35%
Jun 262.21%
Jun 262.14%
May 262.03%
May 262.14%
May 262.31%
May 262.05%
May 263.37%
Apr 263.98%
Apr 263.64%
Apr 264.19%
Apr 263.95%
Mar 264.44%
Mar 264.08%
Mar 263.97%
Mar 263.49%
Feb 264.23%
Feb 263.94%
Feb 263.81%
Feb 263.41%
Jan 263.28%
Jan 263.12%
Jan 263.21%
Jan 262.98%
Jan 262.98%
Dec 252.98%
Dec 253.08%
Dec 253.04%
Dec 253.31%
Nov 253.35%
Nov 253.57%
Nov 253.49%
Nov 253.34%
Oct 252.58%
Oct 252.76%
Oct 252.96%
Oct 252.91%
Oct 252.88%
Sep 252.69%
Sep 252.51%
Sep 252.49%
Sep 252.47%
Aug 252.46%
Aug 252.47%
Aug 252.46%
Aug 252.53%
Aug 256.08%
Jul 255.36%
Jul 255.34%
Jul 255.36%
Jul 254.72%
Jun 255.04%
Jun 255.1%
Jun 254.87%
Jun 254.19%
May 254.3%
May 254.33%
May 253.85%
May 253.98%
May 251.37%
Apr 251.42%
Apr 251.59%
Apr 251.55%
Apr 251.57%
Mar 251.34%
Mar 251.26%
Mar 251.32%
Mar 250.92%
Feb 250.84%
Feb 250.74%
Feb 250.61%
Feb 250.61%
Jan 250.65%
Jan 250.65%
Jan 250.67%
Jan 250.68%
Jan 250.66%
Dec 240.65%
Dec 240.65%
Dec 240.68%
Dec 240.72%
Nov 240.77%
Nov 240.76%
Nov 240.79%
Nov 240.74%
Nov 240.61%
Oct 240.59%
Oct 240.59%
Price to Sales
02468med 2.39Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Price to Sales by quarter
PeriodPrice to Sales
Sep 262.26
Sep 262.26
Aug 262.25
Aug 262.25
Aug 261.69
Aug 261.63
Jul 262.07
Jul 261.95
Jul 262.28
Jul 262.19
Jul 262.08
Jun 261.87
Jun 261.64
Jun 261.74
Jun 261.8
May 261.9
May 261.8
May 261.67
May 261.88
May 261.88
Apr 261.59
Apr 261.74
Apr 261.51
Apr 261.61
Mar 261.43
Mar 261.55
Mar 261.6
Mar 261.82
Feb 261.66
Feb 261.79
Feb 261.84
Feb 262.06
Jan 262.14
Jan 262.25
Jan 262.19
Jan 262.36
Jan 262.36
Dec 252.36
Dec 252.28
Dec 252.31
Dec 252.12
Nov 252.1
Nov 251.97
Nov 252.02
Nov 252.1
Oct 252.51
Oct 252.35
Oct 252.19
Oct 252.23
Oct 252.25
Sep 252.41
Sep 252.58
Sep 252.6
Sep 252.63
Aug 252.64
Aug 252.63
Aug 252.64
Aug 252.57
Aug 252.37
Jul 252.68
Jul 252.69
Jul 252.68
Jul 253.05
Jun 252.85
Jun 252.82
Jun 252.96
Jun 253.43
May 253.34
May 253.32
May 253.74
May 253.61
May 253.85
Apr 253.72
Apr 253.32
Apr 253.4
Apr 253.36
Mar 253.93
Mar 254.17
Mar 253.99
Mar 254.21
Feb 254.63
Feb 255.24
Feb 256.39
Feb 256.33
Jan 256
Jan 255.96
Jan 255.79
Jan 255.72
Jan 255.86
Dec 245.93
Dec 245.93
Dec 245.68
Dec 245.4
Nov 245.03
Nov 245.11
Nov 244.88
Nov 245.21
Nov 245
Oct 245.14
Oct 245.15
EV/EBITDA
100120140160180med 165.35Aug 26Aug 26Aug 26Aug 26Sep 26Sep 26
WEAV EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 26165.83
Sep 26166.3
Aug 26165.35
Aug 26165.35
Aug 26121.81
Aug 26117.77
Price/Operating Cashflow
0255075100125med 34.45Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2634.55
Sep 2634.64
Aug 2634.45
Aug 2634.45
Aug 2625.8
Aug 2625
Jul 2642.63
Jul 2640.22
Jul 2647.13
Jul 2645.18
Jul 2642.89
Jun 2638.59
Jun 2633.9
Jun 2635.98
Jun 2637.09
May 2639.24
May 2637.22
May 2634.42
May 2638.72
May 2625.62
Apr 2621.7
Apr 2623.75
Apr 2620.63
Apr 2621.88
Mar 2619.47
Mar 2621.16
Mar 2621.74
Mar 2624.77
Feb 2621.23
Feb 2622.83
Feb 2623.59
Feb 2626.32
Jan 2627.38
Jan 2628.77
Jan 2628.01
Jan 2630.2
Jan 2630.2
Dec 2530.16
Dec 2529.19
Dec 2529.53
Dec 2527.13
Nov 2526.87
Nov 2525.15
Nov 2525.78
Nov 2526.91
Oct 2533.81
Oct 2531.62
Oct 2529.48
Oct 2530.02
Oct 2530.34
Sep 2532.49
Sep 2534.72
Sep 2535
Sep 2535.36
Aug 2535.5
Aug 2535.41
Aug 2535.54
Aug 2534.54
Aug 2514.99
Jul 2516.99
Jul 2517.05
Jul 2516.99
Jul 2519.29
Jun 2518.06
Jun 2517.84
Jun 2518.72
Jun 2521.75
May 2521.18
May 2521.05
May 2523.66
May 2522.89
May 2555.61
Apr 2553.71
Apr 2547.94
Apr 2549.12
Apr 2548.46
Mar 2556.69
Mar 2560.25
Mar 2557.67
Mar 2573.5
Feb 2580.89
Feb 2591.54
Feb 25111.57
Feb 25110.48
Jan 25104.77
Jan 25104
Jan 25101.11
Jan 2599.82
Jan 25102.39
Dec 24103.48
Dec 24103.48
Dec 2499.25
Dec 2494.3
Nov 2487.76
Nov 2489.3
Nov 2485.19
Nov 2491.03
Nov 2493.06
Oct 2495.54
Oct 2495.76
Price to Book
05101520med 6.97Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WEAV Price to Book by quarter
PeriodPrice to Book
Sep 266.85
Sep 266.87
Aug 266.83
Aug 266.83
Aug 265.12
Aug 264.96
Jul 266.17
Jul 265.82
Jul 266.82
Jul 266.54
Jul 266.21
Jun 265.59
Jun 264.91
Jun 265.21
Jun 265.37
May 265.68
May 265.39
May 264.98
May 265.6
May 265.45
Apr 264.62
Apr 265.06
Apr 264.39
Apr 264.66
Mar 264.15
Mar 264.51
Mar 264.63
Mar 265.27
Feb 264.85
Feb 265.22
Feb 265.39
Feb 266.02
Jan 266.26
Jan 266.58
Jan 266.4
Jan 266.9
Jan 266.9
Dec 256.89
Dec 256.67
Dec 256.75
Dec 256.2
Nov 256.14
Nov 255.75
Nov 255.89
Nov 256.15
Oct 257.03
Oct 256.57
Oct 256.13
Oct 256.24
Oct 256.31
Sep 256.75
Sep 257.22
Sep 257.28
Sep 257.35
Aug 257.38
Aug 257.36
Aug 257.39
Aug 257.18
Aug 257.35
Jul 258.33
Jul 258.36
Jul 258.33
Jul 259.46
Jun 258.86
Jun 258.75
Jun 259.18
Jun 2510.67
May 2510.39
May 2510.32
May 2511.6
May 2511.22
May 2511.75
Apr 2511.35
Apr 2510.13
Apr 2510.38
Apr 2510.24
Mar 2511.98
Mar 2512.73
Mar 2512.19
Mar 2511.98
Feb 2513.18
Feb 2514.92
Feb 2518.18
Feb 2518
Jan 2517.07
Jan 2516.95
Jan 2516.48
Jan 2516.27
Jan 2516.68
Dec 2416.86
Dec 2416.86
Dec 2416.17
Dec 2415.37
Nov 2414.3
Nov 2414.55
Nov 2413.88
Nov 2414.83
Nov 2413.4
Oct 2413.75
Oct 2413.78
Weave Communications, Inc.
WEAV
Stockpicker

Video analysis: WEAV

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: WEAV

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

globenewswire.com · 9 Sep 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

businesswire.com · 1 Sep 2026

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. “Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that kn.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

globenewswire.com · 24 Aug 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - WEAV, BRBS, TDAC and UHG

gurufocus.com · 23 Aug 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - WEAV, BRBS, TDAC and UHG

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - WEAV, BRBS, TDAC and UHG PR Newswire

Weave Communications Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Weave Communications, Inc. - WEAV

businesswire.com · 21 Aug 2026

Weave Communications Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Weave Communications, Inc. - WEAV

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Weave Communications, Inc. (NYSE: WEAV) to Francisco Partners. Under the terms of the proposed transaction, shareholders of Weave will receive $7.40 in cash for each share of Weave that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy

businesswire.com · 20 Aug 2026

Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy

LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, today released its 2026 State of Healthcare Pulse Survey, a survey of 285 owners, office managers, and front desk staff across dental, specialty medical, optometry, and veterinary practices. The findings point to a clear consensus: manual administrative work in disconnected systems is the biggest drag on healthcare practices, and interest in AI i.

Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders

globenewswire.com · 19 Aug 2026

Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Shareholder Alert: Ademi LLP investigates whether Weave Communications, Inc. is obtaining a Fair Price for Public Shareholders

gurufocus.com · 19 Aug 2026

Shareholder Alert: Ademi LLP investigates whether Weave Communications, Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Weave Communications, Inc. is obtaining a Fair Price for Public Shareholders PR

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.